Kymera Therapeutics posts $1.6B year-end cash estimate

Kymera Therapeutics, Inc. reported a preliminary estimate of approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported a preliminary estimate of approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025. These figures are unaudited, form part of its fourth-quarter and full-year 2025 results, and may change as the year-end audit is completed.

The company also provided a business update and outlined its key 2026 objectives and strategy to advance its leading portfolio of immunology programs in a press release furnished as Exhibit 99.1. Kymera plans to discuss these topics in meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference.

8-K Event Classification

2 items: 2.02, 7.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kymera Therapeutics (KYMR) disclose in this 8-K filing?

Kymera Therapeutics disclosed a preliminary estimate of its cash, cash equivalents and marketable securities as of December 31, 2025, and furnished a business update and 2026 objectives in a press release attached as Exhibit 99.1.

How much cash did Kymera Therapeutics (KYMR) estimate holding at year-end 2025?

Kymera Therapeutics estimated it had approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025.

Are Kymera Therapeutics' preliminary 2025 figures audited?

No. The company stated that the information, including the estimated $1.6 billion cash balance, is unaudited and preliminary, and that the audit of its 2025 consolidated financial statements is ongoing and could result in changes.

What future plans did Kymera Therapeutics (KYMR) highlight for 2026?

Kymera highlighted key 2026 objectives and strategy focused on advancing its leading portfolio of immunology programs, as described in the press release furnished as Exhibit 99.1.

What is Exhibit 99.1 in Kymera Therapeutics' 8-K?

Exhibit 99.1 is a press release issued by Kymera Therapeutics on January 13, 2026, which includes the preliminary cash balance, a business update, and further details on its 2026 key objectives and outlook.

What investor outreach is Kymera Therapeutics conducting around this disclosure?

Kymera stated it will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/13/2026 - 07:08 AM Learn about SEC filing dates

false 0001815442 0001815442 2026-01-13 2026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2026

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KYMR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026, Kymera Therapeutics, Inc. (the “Company”) issued a press release announcing its preliminary cash balance as of December 31, 2025, a business update and further details on its 2026 key objectives and outlook. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company announced on January 13, 2025, that it estimates it had approximately $1.6 billion of cash, cash equivalents and marketable securities as of December 31, 2025.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the three months and year ended December 31, 2025. The audit of the Company’s consolidated financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information set forth above.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 13, 2026, the Company issued a press release outlining its key 2026 objectives and strategy to advance its leading portfolio of immunology programs. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026.

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Kymera Therapeutics, Inc. on January 13, 2026, furnished herewith.
104		Cover Page Interactive Data (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Kymera Therapeutics, Inc.
Date: January 13, 2026				By:		/s/ Nello Mainolfi
						Nello Mainolfi, Ph.D.
						President and Chief Executive Officer